NASA Research on the Effects of Space Travel on Mitochondria
Steven Engle, CEO of CohBar, Inc, a clinical stage biotechnology company discusses his article in “Grit Daily” (Jan 8, 2021) on NASA’s breakthrough study published in “Cell” (Nov 25, 2020) on the effects of space travel on mitochondria.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Surgery. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Surgery and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Surgery?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Steven Engle, CEO of CohBar, Inc, a clinical stage biotechnology company discusses his article in “Grit Daily” (Jan 8, 2021) on NASA’s breakthrough study published in “Cell” (No…
- Key Point: Engle joined CohBar as Chief Executive Officer and Director in 2019.
- Key Point: From 2011 to 2019, he served as the Chief Executive Officer of Averigon, an advisory firm to the life science industry.
- Key Point: Engle was Chairman, Chief Executive Officer and President of XOMA Corporation (NASDAQ: XOMA), a publicly traded biotechnology company developing antibody therapeutics for multip…
- Key Point: From 1993 to 2006, he held several executive management roles including serving as Chairman and Chief Executive Officer at La Jolla Pharmaceutical Company (NASDAQ: LJPC), a publ…
Mr. Engle joined CohBar as Chief Executive Officer and Director in 2019. From 2011 to 2019, he served as the Chief Executive Officer of Averigon, an advisory firm to the life science industry. From 2007 to 2011, Mr. Engle was Chairman, Chief Executive Officer and President of XOMA Corporation (NASDAQ: XOMA), a publicly traded biotechnology company developing antibody therapeutics for multiple diseases. From 1993 to 2006, he held several executive management roles including serving as Chairman and Chief Executive Officer at La Jolla Pharmaceutical Company (NASDAQ: LJPC), a publicly traded biotechnology company developing therapeutics for autoimmune diseases. Mr. Engle is chairman of Prescient Therapeutics (ASX: PTX), and a director on the boards of AROA Biosurgery (AUS: ARX) and Author-it Software Corporation. He is a former director of the board of the industry associations, BIO, BayBio and BIOCOM. Mr. Engle received a B.S. in Electrical Engineering with a focus in biomedical engineering and an M.S. in Electrical Engineering from the University of Texas, Austin.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



